Introduction {#sec1-1}
============

Aminoglycoside antibiotics are the most commonly used worldwide in the treatment of gram (-)negative bacterial infections. However, aminoglycosides induce nephrotoxicity in observed 10-20% of therapeutic courses.\[[@ref1]\] The widespread therapeutic use of the gentamicin is limited because of its nephrotoxic side effect and oxidative damage which can lead to acute renal failure.\[[@ref1][@ref2][@ref3]\]

Although the mechanism underlying gentamicin-induced renal cellular damage has not been entirely elucidated, generation of superoxide anion, hydrogen peroxide (H~2~O~2~) and hydroxyl radicals has been attributed to its deleterious effect on the kidney.\[[@ref4][@ref5]\] An association between nephrotoxicity and oxidative stress has been confirmed in many experimental models.\[[@ref6][@ref7]\] The possible involvement of the L-arginine-Nitric oxide (NO) pathway in gentamicin-induced nephrotoxicity has been suggested by Rivas-Cabanero *et al*. These investigators reported increased glomerular synthesis of NO in rats with gentamicin-induced renal failure.\[[@ref8]\]

Arginine, an essential amino acid, has a positively charged guanidine group. Arginine is well-designed to bind the phosphate anion, and is often found in the active centers of proteins that bind phosphorylated substrates. As a cation, arginine plays an important role in maintaining the overall charge balance of a protein. L-Arginine has been intensively investigated, mainly since it is a precursor of NO that is a highly reactive and multifunctional molecule involved in many physiological processes, such as cardiovascular system, nervous system and immunological reactions.\[[@ref9]\] On the other hand, D-arginine is frequently used in studies on L-arginine/NO pathway is an inactive form of L-arginine, because the D-enantiomer is not a substrate for the stereospecific NO synthase.\[[@ref10][@ref11][@ref12][@ref13][@ref14]\]

Data from recent studies showed that the cationic proteins and peptides, inhibit the uptake of a nephrotoxic drug, gentamicin, which is highly accumulated in the kidneys.\[[@ref15][@ref16]\] Some authors report that L-arginine might have protected tubular function simply by decreasing gentamicin reabsorption in the proximal tubules.\[[@ref17]\]

It is known that gentamicin has an organic polycationic structure. L-arginine consists of a functional cationic group of guanidin and due this cationic structural trait it can reduce gentamicin tubular reabsorption and increase gentamicin urinary excretion via competition. Therefore, in the present study, we aimed to investigate the possible protective effects other than NO synthesis of L-arginine and its inactive isomere D-arginine on gentamicin-induced nephrotoxicity in rats due to their structural similarities using High Performance Liquid Chromatography (HPLC) technique.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Experimental Animals {#sec3-1}

In this study, 42 male Wistar albino rats (appoximately 250--300 g weight) were procured from the Medical Science Experimental Research Center at Cukurova University. Rats were sheltered in metabolic cages at room temperature (24 ± 2°C) under 12 hours daylight, 12 hours dark conditions. The study was approved by the Medical Science Experimental Research Center Ethics Committee.

### Experimental Protocol {#sec3-2}

The rats were divided into six groups and each group consisted of seven rats. The groups were as follows:

Group 1(Control group): This group was treated with normal food and tap waterGroup 2(Gentamicin Group): This group was treated with (100 mg/kg gentamicin) subcutaneous (s.c.) injection for seven daysGroup 3(Gentamicin + L-arginine Group): This group was treated with gentamicin injection and L-arginine (2 g/l) was added to their drinking waterGroup 4(Gentamicin + D- arginine Group): This group was treated with gentamicin injection and D-arginine (2 g/l) was added to their drinking waterGroup 5(Gentamicin + L-arginine + L-NAME Group): This group was treated with gentamicin injection and L-arginine (2 g/l) and L-NAME (100 mg/l) were added to their drinking waterGroup 6 (Gentamicin + D-arginine + L- NAME Group): This group was treated with gentamicin injection and D-arginine (2 g/l) and L-NAME (100 mg/l) was added to in their drinking water.

During seven days water intake and urine volume were followed.

After the gentamicin injection, urine samples were collected on the first (initial), fourth (middle) and eighth day (final) to compare gentamicin levels. Ketamine (40 mg/kg) was given for anesthesia 24 hours after the final injection and intracardiac blood was obtained and animals were killed by decapitation. Providing the aseptic conditions, left kidney was removed by middle abdominal line incision for histopathological examination.

### Biochemical Analysis {#sec3-3}

Blood urea nitrogen (BUN), serum creatinine, sodium (Na^+^), potassium (K^+^) levels were investigated from the blood of experimental animals. In addition, gama glutamyl transferase (GGT), creatinine, Na^+^ K^+^ levels in their urine were measured at Central Laboratory of Cukurova University. The clearance of creatinine (C~Cr~) and fractional Na excretion (FE~Na~) were calculated using the standard methods as below.
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### Histopathology of Kidney {#sec3-4}

The kidneys were treated with paraffine after the formaline (10% solution) fixation and approximately 3-5 μm cross-sections were dyed with hematoxylin--eosin. Tubular necrosis, degenerative variations and tubular regeneration were found under fluorescence microscope.

### Measurement of Gentamicin Levels {#sec3-5}

Gentamicin levels of urine samples were evaluated according to the Kafkas *et al*., (2008) with major modifications.\[[@ref18]\] The samples were stored at −20°C until analysis. HPLC analysis was performed in the Subtropical Fruits Research and Experimental Center Laboratory of Cukurova University. Identification and quantification were conducted using gentamicin (Sigma) standards. HPLC technique was used to identification and quantification of urine gentamicin levels.

Fort this purpose, Hewlett Packard 1100 series, HP-1100 UW dedector (210 nm) and Zorbax SB-C18 (10 cm × 4.6 mm, 1.8 μm, Beckman) column were used and flow speed was applied 1 ml/min.

### Statistical analysis {#sec3-6}

Data was presented as means ± Standard error of mean (S.E.M) for the groups. A one-way variance analysis (One-Way ANOVA) method was used for comparison of results. Comparison of groups were performed using Bonferroni test. The level of significance was set as *P* \< 0.05.

### Experimental Drugs {#sec3-7}

In this study, L-Arginine monohydrochloride, N-nitro-L-arginine methyl ester monohydrochloride, D-Arginine monohydrochloride were procured from Sigma whereas gentamicin sulphate was procured from Schering-Plough.

Results {#sec1-3}
=======

 {#sec2-2}

### Control Group {#sec3-8}

The results of the blood and urine samples on the eighth day were found normally \[Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. The renal particles and kidney tubules with normal structure were seen in the histopathological examination of the kidney tissues (data not shown).

![The comparison of blood urea nitrogen levels of the groups. Data are expressed as means ± S.E.M. for the groups; *n* = 7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test. \*(*P* \< 0.05) vs control group, ^+^(*P* \< 0.05) vs gentamicin group](IJPharm-46-608-g002){#F1}

![The comparison of serum creatinine levels of the groups. Data are expressed asmeans ± S.E.M. for the groups; *n* = 7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test. \*(*P* \< 0.05) vs control group, ^+^(*P* \< 0.05) vs gentamicin group](IJPharm-46-608-g003){#F2}

![The comparison of FENa % (fractional Na excreation) levels of the groups. Data are expressed as means ± S.E.M. for the groups; *n* = 7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test. \*(*P* \< 0.05) vs control group, ^+^(*P* \< 0.05) vs gentamicin group](IJPharm-46-608-g004){#F3}

![The comparison of Ccr (creatinine clearance) values of the groups. Data are expressed as means ± S.E.M. for the groups; *n* = 7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test. \*(*P* \< 0.05) vs control group, ^+^(*P* \< 0.05) vs gentamicin group](IJPharm-46-608-g005){#F4}

###### 

Plasma Na^+^, plasma K^+^ and urine GGT (gama glutamyl transferase) values of the groups. Data are expressed as means±S.E.M. for the groups; *n*=7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test
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### Gentamicin Group {#sec3-9}

Serum creatinine, BUN, FE~Na~ and urine GGT levels increased significantly after 8 days of gentamicin administration compared to the controls *P* \< 0.05 \[Figures [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. This group was also characterized by a significantly lower creatinine clearance. However, there is no significant differences in other parameters. Degenerative changes were observed in the epitelial tissue of tubular epithelial tissue in the group treated with gentamicin. The epithelial cells covering the tubulus showed an increased acidophilic epithelial cell cytoplasm and nuclei couldn't be identified, epithelial cells spilled renal particles abnormal capsular space was determined and also became narrow in some sites. The results of urine gentamicin levels were detected as shown in [Figure 5](#F5){ref-type="fig"}.

![The comparison of urine gentamicin levels of Gentamicin, Gentamicin+L-arginine and Gentamicin+D-arginine applied groups. Data are expressed as means ± S.E.M. for the groups; *n* = 7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test. \*(*P* \< 0.05) vs gentamicin first group, ^+^(*P* \< 0.05) vs gentamicin in middle, and (*P* \< 0.05) vs gentamicin in last group](IJPharm-46-608-g007){#F5}

### Gentamicin + L-arginine Group {#sec3-10}

L-arginine administration provided marked protection manifested as significantly decreased serum creatinine, BUN, FE~Na~ and urine GGT levels and significantly increased creatinine clearance compared to the gentamicin group *P* \< 0.05 \[Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. However, other parameters detected were insignificant.

In this group, renal particles were observed as normal structure, the fallen of tubular epithelium and slight grade degenerative changes were also detected. The group which was applied only gentamicin was compared with the group gentamicin with L-argininine; the urine gentamicine levels were increased and this enhancement found to be statistically significant \[[Figure 5](#F5){ref-type="fig"}\].

### Gentamicin + D-arginine Group {#sec3-11}

Compared to the gentamicin group, D-arginine administration significantly decreased serum creatinine, BUN, FE~Na~ and urine GGT levels and significantly increased creatinine clearance *P* \< 0.05 \[Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. Besides this, other parameters detected were insignificant. In histopathological evaluation, slight grade degenerative changes and intracellular edema, necrosis and intermediate dropping were observed in tubular epithelium, as well.

The group which was applied only gentamicin was compared with the group gentamicin with D-arginine; the urine gentamicin levels were increased significantly \[[Figure 5](#F5){ref-type="fig"}\].

### Gentamicin + L-arginine + L-NAME Group {#sec3-12}

Comparison of gentamicin group, BUN levels increased significantly while other parameters were not found statistically significant \[Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. According to the histopathological evaluation, enlargement of the renal corpuscle space, disappearance of cell details were observed, as well as fallen epithelium and advanced grade structural alternation were observed. As for the comparison with only gentamicin-applied to be group, the levels of gentamicin in urine were not significant \[[Table 2](#T2){ref-type="table"}\].

###### 

The urine gentamicin levels of experimental groups. Data are expressed as means±S.E.M. for the groups; *n*=7 in each group. Statistical analysis was performed by one-way analysis of variance (ANOVA) and comparison of groups were performed using Bonferroni test
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### Gentamicin + D-arginine + L-NAME Group {#sec3-13}

Compared with the gentamicin group, BUN, serum creatinine, FE~Na~, C~Cr~, urine GGT, plasma Na^+^ and plasma K^+^ values were not significant \[Figures [1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\]. According to the histopathological evaulation, deformation observed in kidney tissue and tubular necrosis was high. Among the urine samples, compared with the only gentamicin applied group, gentamicin levels were not significant \[[Table 2](#T2){ref-type="table"}\].

Discussion {#sec1-4}
==========

The aim of the present study was to investigate the possible protective effects of L-arginine and its inactive isomere D-arginine on gentamicin-induced nephrotoxicity in rats due to their structural similarities.

Aminoglycosides are totally eliminated by glomerular filtration and reabsorbed by the proximal tubules. Even therapeutic doses of these antibiotics commonly lead to proximal tubular cell necrosis in humans. This pathology was known due to the accumulation of gentamicin in renal cortex.\[[@ref19][@ref20]\] Similar results were obtained in this study and identification of nephrotoxicity criterias were found to be similar. The administration of gentamicin in rats induced a reduction in glomerular filtration rate as shown by a reduced creatinine clearance and increased serum creatinine. This impairment in glomerular function was accompanied by increased fractional excretion of Na^+^. This indicates proximal tubular dysfunction. The presence of tubular damage was further confirmed by the increased urinary excretion of the GGT and it indicates direct toxic injury. These findings correlated well with the renal morphological examination, which revealed tubular necrosis.

In rats treated with gentamicin and L-arginine together; biochemical and histopathological changes were found to be reversed. These results are similar to the previous reports.\[[@ref21][@ref22]\] However, L-arginine diminished the acute tubular necrosis as well. This effect can be due to the other mechanisms in addition to L-arginine-NO pathway. L-arginine is known as precursor of NO and can be used for nitric oxide synthesis. This amino acid is present and synthesized as endogenous. This includes cationic two functional guanidine groups.\[[@ref23]\] This aminoacid can inhibit tubular reabsorbtion similar to gentamicin which has a cationic character. According to this information, L-Arginine increases the gentamicin excretion in urine. For this purpose, in this study we aimed to identify and quantify gentamicin levels after the injection of gentamicin first day (first), fourth day (middle) and eighth day (last) in urine samples by HPLC technique. As for the L-arginine given groups; urine gentamicin levels were increased statistically compared to only gentamicin given group. This result supports our hypothesis that L-arginin might have protected tubular function simply by decreasing gentamicin reabsorption. But, this increase can be explained as the increase of NO production which is known as a strong vasodilator and this can provide the improvement of hemodynamics. On the other hand, D-arginine has a similar and cationic structure but does not play a role in NO synthesis. We also detected an increase in urine gentamicin levels in D-arginine group. This result showed that the nephroprotective effect of D-arginine also can be explained as cationic characteristic.

The effect of nitric oxide synthase inhibition on renal failure has been investigated. Recent datas provided evidence that endothelial NOS leads to restoration of renal function after injury, while activation of inducible NOS, leading to excessive NO production, causes tubular cytotoxicity and aggravates renal failure. In our study, nephroprotective effects of L-arginine are reversed by L-NAME which is a non-selective inhibitor. It causes tubular deformation by inhibition of eNOS while positive effects of NOS inhibition may be prevented. This result shows that, NO has a major important role on protective effect of L-arginine. Nitric oxide is the most important paracrine modulator and mediator of controlling of renal functions such as renal blood flow, renal autoregulation, glomerular filtration, renin excretion and Na excretion. Nitric oxide plays an important role in diabetic nephropathy, inflammatory glomerular abnormality, acute and chronic kidney failure, effects of nephrotoxicity of medicine and several kidney defective states.\[[@ref24][@ref25]\]

In conclusion, the results of the present study demonstrate that administration of L-arginine and D-arginine has beneficial effects in rats with gentamicin-induced renal failure and that these effects are reversed by the NO-synthase inhibitor L-NAME. In addition, administration of L-arginine and its inactive form, D-arginine increases urine gentamicin levels. Althought it is known that NO has a major role on this protective effect, in our study L-arginine has also protected tubular function simply by decreasing gentamicin reabsorption in the proximal tubules due to having cationic structure. This protective mechanism other than NO synthesis can further be investigated.
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